U. Griesenbach, F. M. Munkonge, S. G. Sumner-Jones, E. Holder, S. N. Smith, A. C. Boyd, D. R. Gill, S. C. Hyde, D. Porteus and E. W. F. W. Alton
Methods in Molecular Biology, vol. 433: Volume 1: Production and In Vivo Applications of Gene Transfer Vectors, 229-242 (978-1-58829-903-1)
Cystic fibrosis (CF) a monogenic lethal disease and, therefore, ideally suited for the development of gene therapy. The first clinical trials were carried out shortly after cloning the CF gene in 1989. Since then, 25 trials have been carried out. Proof of principle for low- level airway gene transfer was established in most, but not all, trials. It is currently unclear whether current gene transfer efficiency will lead to improvements in clinically relevant endpoints such as inflammation or infection. In addition to addressing this important question, we and others are further improving airway gene transfer, by modifying existing and developing new gene transfer agents. Here, we describe pre-clinical methods related to assessing correction of the CF chloride transport defect.